Rossari Biotech (ROSSARI) investor relations material

Executive summary

• Q2 FY26 revenue grew 18% year-over-year, driven by strong volume expansion across HPPC, PSC/TSC, and AHN segments.

• Exports rose 36% YoY in Q2, now contributing 28% of total revenue, reflecting deeper international market penetration.

• Profitability remained steady despite subdued pricing and ongoing investments in new business opportunities.

• New manufacturing capacities commissioned, including 20,000 MT at the base facility and 15,000 MT ethoxylation at Unit Ork/Dahej, with further expansions underway.

• Unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, were approved and reviewed by the Board and Audit Committee.

Financial highlights

• Q2 FY26 consolidated revenue: ₹5,861.07 million, up from ₹4,983.51 million in Q2 FY25; H1 revenue: ₹11,298.23 million, up from ₹9,880.01 million YoY.

• Q2 FY26 EBITDA: ₹71.9 crore, margin at 12.3%; PAT: ₹36.9 crore, margin at 6.3%.

• Standalone Q2 FY26 revenue: ₹4,195.12 million, up from ₹3,359.89 million in Q2 FY25.

• CapEx outflow in H1: INR 142 crores, with an additional INR 20–25 crores expected.

• Exports contributed 28% of sales in Q2 FY26, with export revenue growing 36% YoY.

Outlook and guidance

• Margin guidance for core B2B business remains at 14–16% EBITDA for H2 FY26.

• Profitability expected to improve as new initiatives and investments scale and reach operational maturity.

• Additional investment of up to USD 8 million approved for Saudi Arabia subsidiary to support business expansion, to be completed by March 31, 2027.

• Revenue ramp-up anticipated from new non-EO products and capacity additions, though margin improvement may be gradual due to pricing pressures and tariffs.